Navigation Links
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Date:1/3/2008

Novel non-estrogen oral therapy in development for menopausal symptoms

ANN ARBOR, Mich., Jan. 3 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced positive results from a pivotal Phase 3 study of Ophena(TM) (ospemifene) to treat postmenopausal women with vulvovaginal atrophy, a common condition associated with menopause. Top line data show that the multi-center, double-blind, placebo-controlled study successfully met all of its co-primary endpoints. The study was conducted in 80 U.S. centers and involved more than 800 women. Full results of the study are being submitted to an upcoming scientific meeting for release later in 2008.

Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a treatment for women with postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy. PVS is a common condition in postmenopausal women characterized by symptoms such as vaginal dryness, irritation and pain associated with sexual intercourse. The only currently FDA approved products for this condition all contain the hormone estrogen. However, many women and their physicians avoid using estrogen-containing products due to concerns about the risks of such therapy identified in the Women's Health Initiative (WHI) and other studies.

"These results are very exciting and we believe demonstrate that Ophena(TM) has the potential to bring clear clinical benefit to women affected by PVS, many of whom have had only estrogen therapy as a treatment option for their condition to date," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe Ophena(TM) could provide the first non- estrogen prescription treatment alternative for this condition. QuatRx is well positioned to continue with our plans to advance this exciting product to commercialization, pending regulatory review and approval."

This pivotal Phase 3 study was designed to evaluate the efficacy of Ophena(TM) versus p
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Nopras Technologies ( www.nopras-tech.com ) has ... to the position of Director, Business Development ... from Bio-Investigations Ltd., a specialized global venture capital ... years ago, focused in the fields of human, ... graduate degrees in biology, biochemistry, and business from ...
(Date:11/18/2014)... , Nov. 18, 2014 ResMed (NYSE: ... the all-new S+, the world,s first non-contact, personal sleep monitoring ... in the United States and from ... by ResMed App now integrates with Apple HealthKit in iOS8 ... health and fitness. The user report can also be shared with ...
(Date:11/18/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the receipt of approval from the U.S. Food and ... IDEAL IMPLANT ® Saline-filled Breast Implant ... existing augmentation implants. The FDA approval of the IDEAL ... studies and data including a U.S. clinical trial that ...
Breaking Medicine Technology:Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 2Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 3ResMed's New S+ Consumer Sleep Monitor Now Integrates With Apple HealthKit 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3
... , MINNEAPOLIS, Dec. 10 Uroplasty, Inc. (NYSE Amex: ... manufactures and markets innovative proprietary products to treat voiding ... Trial of its Urgent® PC Neuromodulation System that will ... THE JOURNAL OF UROLOGY® . The Urgent PC ...
... , NEW YORK, Dec. 10 , ... greater value to customers. Five strategic business units ... Lilly advances ranking to ninth in worldwide pharmaceutical ... Europe and globally. R&D pipeline boasts more than ...
Cached Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18
(Date:11/18/2014)... Concord, Massachusetts (PRWEB) November 18, 2014 ... focused on the development and commercialization of specialized ... Patent Office has granted Cristcot a patent for ... suppository applicator, Sephure®. , The patent ... and the property rights have been assigned to ...
(Date:11/18/2014)... Steven Reinberg HealthDay ... -- People with the abnormal heartbeat known as atrial ... risk for bleeding and blood clots, according to a ... patients who took a blood thinner along with one ... aspirin, ibuprofen (Motrin), naproxen (Aleve) and celecoxib (Celebrex). ...
(Date:11/18/2014)... BellasDress has announced the launch of 85 new models of ... fabrics, the new styles of prom dresses have attracted many ... gifts in a variety of colors and styles. , “We ... are created by top designers,” said the vice president for ... our sales team and more than one client has told ...
(Date:11/18/2014)... Virginia Beach, Virginia (PRWEB) November 18, 2014 ... employees experience frustrating situations with print devices like unforeseen ... occur when they don't have time to find another ... fix the issue. The IT department is likely tied ... Sound familiar? , That’s where Electronic ...
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat 2Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4
... Virginia - Researchers at the Virginia Commonwealth University have ... with advanced periodontitis may be responsible for increasing the ... ,Periodontitis is the inflammation of the supporting ... linked its presence with a host of diseases including ...
... and causing havoc the bird flu has spread its wings over ... ,This has sent panic waves in the government as well ... flu tests are now being conducted to determine if the virus ... Asia. ,A state of emergency has been called for by ...
... sector of England has both doctors and nurses of Indian ... 20 percent.// The National Health Service (NHS) of England ... Hospital, in the Wellchild awards. ,Jaswant is ... been honoured in a national competition. Children's health charity WellChild ...
... Scott Belcher, PhD, did a study that Bisphenol A ... doses.' , ,Worded by Dr. Belcher, 'These new ... rapid signalling mechanisms are active in the developing and ... with sexual differences or reproductive functions,' ,'BPA ...
... computer screens is bad for the eyes since it leads to ... tearing // . Researchers at the Ohio State University say that ... for dry eye. ,"People tend to squint when they ... the blink rate go way down," said lead researcher James Sheedy, ...
... anti-clotting drug, run the risk of either serious complications ... a new research // . The Wake Forest University ... that the study aimed at finding out if an ... antibodies prior to the surgery. ,Heparin is ...
Cached Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2Health News:Food packaging with Bisphenol A damages the brain 2
LASIK Retreatment Forceps - Also available in Titanium...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: